Algernon Pharmaceuticals Announces Plans for a Phase 2 Ifenprodil Chronic Cough Study in the U.S.
Ryan Allway September 20th, 2021 Psychedelics VANCOUVER, British Columbia, Sept. 20, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF) (FRANKFURT: AGW) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it plans to file a pre-IND (Investigational New Drug) meeting... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )